DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
AVEO and Astellas Report FDA.
Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma.
Press release 5 2 2013;
http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=1814508& highlight=
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.